New York State Teachers Retirement System Has $5.02 Million Holdings in Organon & Co. (NYSE:OGN)

New York State Teachers Retirement System raised its position in Organon & Co. (NYSE:OGN - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,226 shares of the company's stock after acquiring an additional 58,321 shares during the quarter. New York State Teachers Retirement System owned approximately 0.14% of Organon & Co. worth $5,021,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Organon & Co. by 1.8% in the third quarter. Vanguard Group Inc. now owns 30,230,471 shares of the company's stock worth $707,394,000 after buying an additional 536,373 shares in the last quarter. State Street Corp grew its position in shares of Organon & Co. by 1.7% during the second quarter. State Street Corp now owns 13,044,754 shares of the company's stock worth $271,461,000 after purchasing an additional 214,766 shares in the last quarter. Invesco Ltd. grew its position in shares of Organon & Co. by 23.7% during the third quarter. Invesco Ltd. now owns 10,240,630 shares of the company's stock worth $177,777,000 after purchasing an additional 1,963,682 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Organon & Co. by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 9,280,300 shares of the company's stock worth $161,106,000 after purchasing an additional 436,034 shares in the last quarter. Finally, Amundi grew its position in shares of Organon & Co. by 98.9% during the fourth quarter. Amundi now owns 3,407,333 shares of the company's stock worth $104,399,000 after purchasing an additional 1,693,968 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group increased their target price on Organon & Co. from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 20th.

Insider Activity

In other Organon & Co. news, insider Kirke Weaver purchased 2,720 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now owns 15,181 shares of the company's stock, valued at $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.17% of the company's stock.

Organon & Co. Stock Down 4.5 %

Organon & Co. stock traded down $0.83 during midday trading on Friday, reaching $17.45. 2,976,297 shares of the stock traded hands, compared to its average volume of 1,919,908. The stock's fifty day moving average is $17.88 and its 200-day moving average is $15.58. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.79. The stock has a market cap of $4.46 billion, a P/E ratio of 4.36, a PEG ratio of 0.83 and a beta of 0.83.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.55 billion. On average, equities analysts predict that Organon & Co. will post 4.08 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 6.42%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.'s payout ratio is 28.00%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.